Identifying and managing adverse drug reactions: Qualitative analysis of patient reports to the UK yellow card scheme

被引:3
|
作者
O'Donovan, Bernadine [1 ,2 ]
Rodgers, Ruth M. [2 ]
Cox, Anthony R. [3 ]
Krska, Janet [2 ]
机构
[1] Royal Coll Surg Ireland RCSI, Dublin, Ireland
[2] Univ Greenwich & Kent, Medway Sch Pharm, Greenwich, England
[3] Univ Birmingham, Coll Med & Dent Sci, Birmingham, W Midlands, England
关键词
adverse drug reactions; identification; management; patient reports; pharmacovigilance; yellow card; STEVENS-JOHNSON SYNDROME; MEDICATION; PHARMACOVIGILANCE; EXPERIENCES; INFORMATION; MEDICINES;
D O I
10.1111/bcp.15263
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction Adverse drug reactions (ADRs) can have significant negative impact on peoples' daily lives, with physical, economic, social and/or psychological effects. Patient reporting of ADRs has been facilitated by pharmacovigilance systems across Europe. However, capturing data on patients' experiences of ADRs has proved challenging. Existing patient reports to the UK Yellow Card Scheme contain free-text comments which could be useful sources of information. Objectives To investigate patients' experiences of ADRs and their impact on patients as described in free-text data within patient Yellow Card (YC) reports submitted to the Medicines and Healthcare products Regulatory Agency. Methods A qualitative review of narrative texts was conducted on free-text data from 2255 patient YC reports from July to December 2015. Results Three key narrative themes emerged from analysis of the free-text data in 2255 reports: (1) identification of ADRs, (2) severity and impact of ADRs, and (3) management of ADRs. Temporal associations were the most common method of identification followed by differential diagnoses and confirmation with information sources such as healthcare professionals (HCPs). A combination of explicit and implicit impacts were described: physical, psychological, economic and social effects often persisted and caused serious disruption to many patients' lives. A range of strategies were used to manage ADRs, including consultation with HCPs, stopping/reducing the medicine or taking medicines to alleviate symptoms. Conclusion Free-text data from YC reports has been an underutilised resource to date, but this research has confirmed its potential value to pharmacovigilance and medication safety research.
引用
收藏
页码:3434 / 3446
页数:13
相关论文
共 50 条
  • [2] How Patient Reporters Identify Adverse Drug Reactions A Qualitative Study of Reporting via the UK Yellow Card Scheme
    Krska, Janet
    Anderson, Claire
    Murphy, Elizabeth
    Avery, Anthony J.
    [J]. DRUG SAFETY, 2011, 34 (05) : 429 - 436
  • [3] Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK
    McLernon, David J.
    Bond, Christine M.
    Lee, Amanda J.
    Watson, Margaret C.
    Hannaford, Philip C.
    Fortnum, Heather
    Krska, Janet
    Anderson, Claire
    Murphy, Elizabeth
    Avery, Anthony
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (05) : 523 - 531
  • [4] Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys
    Avery, A. J.
    Anderson, C.
    Bond, C. M.
    Fortnum, H.
    Gifford, A.
    Hannaford, P. C.
    Hazell, L.
    Krska, J.
    Lee, A. J.
    McLernon, D. J.
    Murphy, E.
    Shakir, S.
    Watson, M. C.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2011, 15 (20) : 1 - +
  • [5] The yellow card scheme: Evaluation of patient reporting of suspected adverse drug reactions
    Ekins-Daukes, S.
    Irvine, D.
    Wise, L.
    Fiddes, S.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S105 - S105
  • [6] How Patient Reporters Identify Adverse Drug ReactionsA Qualitative Study of Reporting via the UK Yellow Card Scheme
    Janet Krska
    Claire Anderson
    Elizabeth Murphy
    Anthony J. Avery
    [J]. Drug Safety, 2011, 34 : 429 - 436
  • [7] The Yellow Card Scheme: Patient Reporting of Adverse Drug Reactions and Signals they have Generated
    Foy, M.
    Gandhi, S.
    Suri, S.
    Cumber, S.
    Jadeja, M. M.
    [J]. DRUG SAFETY, 2011, 34 (10) : 903 - 903
  • [8] Assessing the usability of methods of public reporting of adverse drug reactions to the UK Yellow Card Scheme
    Anderson, Claire
    Gifford, Alison
    Avery, Anthony
    Fortnum, Heather
    Murphy, Elizabeth
    Krska, Janet
    Bond, Christine
    [J]. HEALTH EXPECTATIONS, 2012, 15 (04) : 433 - 440
  • [9] Public awareness in Wales of the UK Yellow Card scheme for reporting suspected adverse drug reactions
    Bracchi, Robert C.
    Tseliou, Foteini
    Copeland, Lauren
    Routledge, Philip A.
    Thomas, Alison
    Woods, Fiona
    Adams, Alana
    Walker, Jenna
    Jadeja, Mitul
    Atkinson, Mark D.
    Ashfield-Watt, Pauline
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (08) : 3344 - 3348
  • [10] Making medicines safer: analysis of patient reports to the UK's Yellow Card Scheme
    O'Donovan, B.
    Rodgers, Ruth M.
    Cox, Anthony R.
    Krska, Janet
    [J]. EXPERT OPINION ON DRUG SAFETY, 2019, 18 (12) : 1237 - 1243